Jump to content

Tirzepatide: Difference between revisions

From Pharmacopedia
[unchecked revision][unchecked revision]
← Older edit

MDElliottMD (talk | contribs)

3 user groups
5,187 edits
VisualWikitext
Fix Cargo VARCHAR(300) overflow: blank structure, shorten mechanism, move chemistry/mechanism prose to PK/PD
Strip Category:MedCategory marker per interface-claude 2026-05-20 hygiene order: this page is a medicine, narrative, wiki-meta page, or stylesheet rather than a class-overview category, so it should not carry the MedCategory tag. Class memberships and other tags preserved.
 
(2 intermediate revisions by the same user not shown)
Line 21: Line 21:
| intro = Tirzepatide is the first '''dual GIP / GLP-1 receptor agonist''' ("twincretin") approved for clinical use. Eli Lilly markets it as '''[[Mounjaro]]''' (for [[type 2 diabetes mellitus]], FDA-approved May 2022)<ref name="mounjaro-label"/> and '''[[Zepbound]]''' (for [[obesity]], November 2023;<ref name="zepbound-label"/> later expanded to [[obstructive sleep apnea]] in obesity in December 2024<ref name="surmount-osa">Malhotra A, Grunstein RR, Fietze I et al. (2024). Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). ''NEJM'' 391(13):1193–205. doi:10.1056/NEJMoa2404881</ref>).
| intro = Tirzepatide is the first '''dual GIP / GLP-1 receptor agonist''' ("twincretin") approved for clinical use. Eli Lilly markets it as '''[[Mounjaro]]''' (for [[type 2 diabetes mellitus]], FDA-approved May 2022)<ref name="mounjaro-label"/> and '''[[Zepbound]]''' (for [[obesity]], November 2023;<ref name="zepbound-label"/> later expanded to [[obstructive sleep apnea]] in obesity in December 2024<ref name="surmount-osa">Malhotra A, Grunstein RR, Fietze I et al. (2024). Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). ''NEJM'' 391(13):1193–205. doi:10.1056/NEJMoa2404881</ref>).


In direct comparison, tirzepatide produced greater HbA1c reduction and greater weight loss than [[semaglutide]] at maximum approved doses (SURPASS-2),<ref name="surpass2"/> and the largest weight loss yet reported with an injectable incretin in obesity without diabetes — up to ~22.5% body weight at 72 weeks (SURMOUNT-1).<ref name="surmount1"/>
In direct comparison, tirzepatide produced greater HbA1c reduction and greater weight loss than [[semaglutide]] at maximum approved doses (SURPASS-2),<ref name="surpass2"/> and the largest weight loss yet reported with an injectable incretin in obesity without diabetes, up to ~22.5% body weight at 72 weeks (SURMOUNT-1).<ref name="surmount1"/>


| pharmacokinetics = '''Chemistry'''. 39-amino-acid synthetic peptide; '''dual agonist''' at the [[GIP receptor]] and [[GLP-1 receptor]]. Acylated with a C20 fatty diacid linked via γGlu-2×AEEA spacer for albumin binding → ~5-day half-life enabling weekly dosing.<ref name="coskun2018">Coskun T, Sloop KW, Loghin C et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. ''Mol Metab'' 18:3–14. doi:10.1016/j.molmet.2018.09.009</ref>
| pharmacokinetics = '''Chemistry'''. 39-amino-acid synthetic peptide; '''dual agonist''' at the [[GIP receptor]] and [[GLP-1 receptor]]. Acylated with a C20 fatty diacid linked via γGlu-2×AEEA spacer for albumin binding → ~5-day half-life enabling weekly dosing.<ref name="coskun2018">Coskun T, Sloop KW, Loghin C et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. ''Mol Metab'' 18:3–14. doi:10.1016/j.molmet.2018.09.009</ref>
Line 27: Line 27:
Acylation with a C20 fatty diacid drives non-covalent albumin binding, producing a terminal half-life of ~120 hours and supporting once-weekly subcutaneous dosing.<ref name="coskun2018"/><ref name="mounjaro-label"/> Cleared predominantly by proteolytic catabolism; no CYP-mediated metabolism. Renal and hepatic impairment do not require dose adjustment.<ref name="mounjaro-label"/>
Acylation with a C20 fatty diacid drives non-covalent albumin binding, producing a terminal half-life of ~120 hours and supporting once-weekly subcutaneous dosing.<ref name="coskun2018"/><ref name="mounjaro-label"/> Cleared predominantly by proteolytic catabolism; no CYP-mediated metabolism. Renal and hepatic impairment do not require dose adjustment.<ref name="mounjaro-label"/>


Delayed gastric emptying is greatest during dose escalation and attenuates over time. This can reduce absorption of co-administered oral medicines, including oral contraceptives — clinically relevant during the first 4 weeks of any new dose level.<ref name="mounjaro-label"/>
Delayed gastric emptying is greatest during dose escalation and attenuates over time. This can reduce absorption of co-administered oral medicines, including oral contraceptives, clinically relevant during the first 4 weeks of any new dose level.<ref name="mounjaro-label"/>


| pharmacodynamics = '''Receptor pharmacology'''. Activates both [[GIP receptor|GIP]] and [[GLP-1 receptor|GLP-1]] receptors. The dual mechanism produces greater glucose-dependent insulin secretion, greater weight loss, and a somewhat improved GI tolerability profile relative to selective GLP-1 RAs in head-to-head comparison.<ref name="coskun2018"/><ref name="surpass2">Frías JP et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). ''NEJM'' 385(6):503–15. doi:10.1056/NEJMoa2107519</ref>
| pharmacodynamics = '''Receptor pharmacology'''. Activates both [[GIP receptor|GIP]] and [[GLP-1 receptor|GLP-1]] receptors. The dual mechanism produces greater glucose-dependent insulin secretion, greater weight loss, and a somewhat improved GI tolerability profile relative to selective GLP-1 RAs in head-to-head comparison.<ref name="coskun2018"/><ref name="surpass2">Frías JP et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). ''NEJM'' 385(6):503–15. doi:10.1056/NEJMoa2107519</ref>
Line 37: Line 37:
* In moderate-to-severe OSA with obesity, ~50% reduction in apnea–hypopnea index at 52 wk (SURMOUNT-OSA)<ref name="surmount-osa"/>
* In moderate-to-severe OSA with obesity, ~50% reduction in apnea–hypopnea index at 52 wk (SURMOUNT-OSA)<ref name="surmount-osa"/>


| indications = <indication ref="diabetes-type-2" author="MDElliottMD"/>
| indications = <problem ref="diabetes-type-2" author="MDElliottMD"/>
<indication ref="obesity" author="MDElliottMD"/>
<problem ref="obesity" author="MDElliottMD"/>
<indication ref="osa-obesity" author="MDElliottMD"/>
<problem ref="osa-obesity" author="MDElliottMD"/>


| dosing = <titration slug="mounjaro-standard" author="MDElliottMD" title="Mounjaro — standard T2DM titration">
| dosing = <titration slug="mounjaro-standard" author="MDElliottMD" title="Mounjaro, standard T2DM titration">
2.5 mg SC weekly × 4 weeks (non-therapeutic ramp)
2.5 mg SC weekly × 4 weeks (non-therapeutic ramp)
→ 5 mg SC weekly × ≥4 weeks
→ 5 mg SC weekly × ≥4 weeks
Line 49: Line 49:
→ 15 mg weekly (max)<ref name="mounjaro-label"/>
→ 15 mg weekly (max)<ref name="mounjaro-label"/>


Hold at any tolerated dose if response is adequate. Slow titration is preferred in any patient with significant GI symptoms — holding 8–12 weeks before advancing is reasonable.
Hold at any tolerated dose if response is adequate. Slow titration is preferred in any patient with significant GI symptoms, holding 8–12 weeks before advancing is reasonable.
</titration>
</titration>


<titration slug="zepbound-standard" author="MDElliottMD" title="Zepbound — standard obesity titration">
<titration slug="zepbound-standard" author="MDElliottMD" title="Zepbound, standard obesity titration">
2.5 mg SC weekly × 4 weeks (non-therapeutic ramp)
2.5 mg SC weekly × 4 weeks (non-therapeutic ramp)
→ 5 mg SC weekly × ≥4 weeks
→ 5 mg SC weekly × ≥4 weeks
Line 62: Line 62:
| effects = * '''Early satiety''' and reduced food intake<ref name="surmount1"/>
| effects = * '''Early satiety''' and reduced food intake<ref name="surmount1"/>
* '''Food noise quieting''' (also reported with semaglutide){{Citation needed}}
* '''Food noise quieting''' (also reported with semaglutide){{Citation needed}}
* '''Nausea''' — dose-dependent, worst during titration steps<ref name="mounjaro-label"/>
* '''Nausea''', dose-dependent, worst during titration steps<ref name="mounjaro-label"/>
* '''Constipation or diarrhea''' (variable)<ref name="mounjaro-label"/>
* '''Constipation or diarrhea''' (variable)<ref name="mounjaro-label"/>
* '''Decreased appetite''' (clinically the desired effect)<ref name="mounjaro-label"/>
* '''Decreased appetite''' (clinically the desired effect)<ref name="mounjaro-label"/>
* '''Injection-site reactions''' — uncommon, generally mild<ref name="mounjaro-label"/>
* '''Injection-site reactions''', uncommon, generally mild<ref name="mounjaro-label"/>


GI tolerability appears modestly better than selective GLP-1 RAs at comparable HbA1c / weight-loss endpoints,{{Citation needed}} possibly reflecting the additional GIP-receptor activity.
GI tolerability appears modestly better than selective GLP-1 RAs at comparable HbA1c / weight-loss endpoints,{{Citation needed}} possibly reflecting the additional GIP-receptor activity.
Line 71: Line 71:
| interactions = <pharmaInteractions/>
| interactions = <pharmaInteractions/>


| pregnancy_details = Avoid. Animal embryofetal toxicity is documented.<ref name="mounjaro-label"/> Discontinue ≥1 month before planned conception. Clinically important interaction: tirzepatide reduces absorption of oral contraceptives during initiation and dose escalation — counsel patients to switch to a non-oral or barrier method for at least the first 4 weeks of each new dose level.<ref name="mounjaro-label"/>
| pregnancy_details = Avoid. Animal embryofetal toxicity is documented.<ref name="mounjaro-label"/> Discontinue ≥1 month before planned conception. Clinically important interaction: tirzepatide reduces absorption of oral contraceptives during initiation and dose escalation, counsel patients to switch to a non-oral or barrier method for at least the first 4 weeks of each new dose level.<ref name="mounjaro-label"/>


| monitoring = * Baseline: HbA1c, weight, BP, renal function, lipid panel
| monitoring = * Baseline: HbA1c, weight, BP, renal function, lipid panel
* Personal or family history of MTC or [[MEN2]] — '''contraindicated''', do not start<ref name="mounjaro-label"/>
* Personal or family history of MTC or [[MEN2]], '''contraindicated''', do not start<ref name="mounjaro-label"/>
* Every 3 months for first year: HbA1c, weight, GI tolerability, signs of [[pancreatitis]] or [[gallbladder disease]]<ref name="mounjaro-label"/>
* Every 3 months for first year: HbA1c, weight, GI tolerability, signs of [[pancreatitis]] or [[gallbladder disease]]<ref name="mounjaro-label"/>
* Annual: renal function, lipids
* Annual: renal function, lipids
Line 97: Line 97:
}}
}}


[[Category:MedCategory]]
[[Category:GLP-1 receptor agonists]]
[[Category:GLP-1 receptor agonists]]
[[Category:GIP receptor agonists]]
[[Category:GIP receptor agonists]]

Latest revision as of 18:00, 19 May 2026

GLP-1 receptor agonist · GIP receptor agonist · Antidiabetic · Anti-obesity · "Twincretin"
Tirzepatide
Mounjaro (T2DM), Zepbound (obesity, OSA)
Tirzepatide is the first dual GIP / GLP-1 receptor agonist ("twincretin") approved for clinical use. Eli Lilly markets it as Mounjaro (for type 2 diabetes mellitus, FDA-approved May 2022)[1] and Zepbound (for obesity, November 2023;[2] later expanded to obstructive sleep apnea in obesity in December 2024[4]). In direct comparison, tirzepatide produced greater HbA1c reduction and greater weight loss than semaglutide at maximum approved doses (SURPASS-2),[5] and the largest weight loss yet reported with an injectable incretin in obesity without diabetes, up to ~22.5% body weight at 72 weeks (SURMOUNT-1).[3]

Experience

👥 No personal reports yet
⚕ No clinical reports yet

Log in to add your own experience.

Problems

Type 2 diabetes mellitus—
Obesity—
Obstructive sleep apnea in obesity—
+ Add a problem

Titration strategies

Mounjaro, standard T2DM titration0
2.5 mg SC weekly × 4 weeks (non-therapeutic ramp)

→ 5 mg SC weekly × ≥4 weeks → 7.5 mg weekly × ≥4 weeks if needed → 10 mg weekly × ≥4 weeks if needed → 12.5 mg weekly × ≥4 weeks if needed → 15 mg weekly (max)[1]

Hold at any tolerated dose if response is adequate. Slow titration is preferred in any patient with significant GI symptoms, holding 8–12 weeks before advancing is reasonable.
Zepbound, standard obesity titration0
2.5 mg SC weekly × 4 weeks (non-therapeutic ramp)

→ 5 mg SC weekly × ≥4 weeks → 7.5 mg → 10 mg → 12.5 mg → 15 mg weekly (max), each step held ≥4 weeks[2]

Maintenance is generally 5, 10, or 15 mg/wk depending on response and tolerability. The intermediate steps (7.5 / 12.5 mg) exist to ease titration but are not typical maintenance doses.

+ Add a titration strategy

Effects

  • Early satiety and reduced food intake[3]
  • Food noise quieting (also reported with semaglutide)[citation needed]
  • Nausea, dose-dependent, worst during titration steps[1]
  • Constipation or diarrhea (variable)[1]
  • Decreased appetite (clinically the desired effect)[1]
  • Injection-site reactions, uncommon, generally mild[1]

GI tolerability appears modestly better than selective GLP-1 RAs at comparable HbA1c / weight-loss endpoints,[citation needed] possibly reflecting the additional GIP-receptor activity.

+ Add an effect

Pharmacokinetics

Chemistry. 39-amino-acid synthetic peptide; dual agonist at the GIP receptor and GLP-1 receptor. Acylated with a C20 fatty diacid linked via γGlu-2×AEEA spacer for albumin binding → ~5-day half-life enabling weekly dosing.[6]

Acylation with a C20 fatty diacid drives non-covalent albumin binding, producing a terminal half-life of ~120 hours and supporting once-weekly subcutaneous dosing.[6][1] Cleared predominantly by proteolytic catabolism; no CYP-mediated metabolism. Renal and hepatic impairment do not require dose adjustment.[1]

Delayed gastric emptying is greatest during dose escalation and attenuates over time. This can reduce absorption of co-administered oral medicines, including oral contraceptives, clinically relevant during the first 4 weeks of any new dose level.[1]

Pharmacodynamics

Receptor pharmacology. Activates both GIP and GLP-1 receptors. The dual mechanism produces greater glucose-dependent insulin secretion, greater weight loss, and a somewhat improved GI tolerability profile relative to selective GLP-1 RAs in head-to-head comparison.[6][5]

At the 15 mg/wk maintenance dose:

  • HbA1c reduction of ~2.0–2.3 percentage points in T2DM[5]
  • Weight loss of ~22.5% body weight at 72 wk in obesity without T2DM (SURMOUNT-1)[3]
  • In T2DM with obesity, ~15.7% weight loss at 72 wk (SURMOUNT-2)[7]
  • In moderate-to-severe OSA with obesity, ~50% reduction in apnea–hypopnea index at 52 wk (SURMOUNT-OSA)[4]

    Interactions

No interactions reported yet.

Pregnancy and lactation

Avoid. Animal embryofetal toxicity is documented.[1] Discontinue ≥1 month before planned conception. Clinically important interaction: tirzepatide reduces absorption of oral contraceptives during initiation and dose escalation, counsel patients to switch to a non-oral or barrier method for at least the first 4 weeks of each new dose level.[1]

Monitoring

  • Baseline: HbA1c, weight, BP, renal function, lipid panel
  • Personal or family history of MTC or MEN2, contraindicated, do not start[1]
  • Every 3 months for first year: HbA1c, weight, GI tolerability, signs of pancreatitis or gallbladder disease[1]
  • Annual: renal function, lipids
  • Pre-procedure: hold weekly dose ≥7 days before any planned anesthesia (per ASA 2024 guidance)[8]

    Patient counseling

  • Slow titration is non-negotiable.
  • Inject SC in abdomen, thigh, or upper arm; rotate sites.[1]
  • GI side effects peak in the first 2–4 weeks of each new dose level, then attenuate.
  • Oral contraceptives: switch to a non-oral / barrier method for at least 4 weeks after starting and after each dose escalation.[1]
  • Hydrate aggressively (volume depletion → AKI is a real risk).[1]
  • Resistance training during weight loss protects lean mass.[citation needed]
  • If a weekly dose is missed: take within 4 days; if >4 days, skip and resume on the next regular day.[1]
  • Surgery: hold dose 7 days pre-op and tell every anesthesiologist.[8]
  • Pregnancy planning: stop ≥1 month before trying to conceive.[1]

    Relevant anecdote

0 0

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

See also

GLP-1 receptor agonist · Semaglutide · Liraglutide · Dulaglutide · Exenatide · Type 2 diabetes mellitus · Obesity · Obstructive sleep apnea

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 1.23 1.24 1.25 US FDA. Mounjaro (tirzepatide) prescribing information. Eli Lilly. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
  2. ↑ 2.0 2.1 2.2 2.3 US FDA. Zepbound (tirzepatide) prescribing information. Eli Lilly. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
  3. ↑ 3.0 3.1 3.2 3.3 Jastreboff AM et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM 387:205–16. doi:10.1056/NEJMoa2206038
  4. ↑ 4.0 4.1 Malhotra A, Grunstein RR, Fietze I et al. (2024). Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). NEJM 391(13):1193–205. doi:10.1056/NEJMoa2404881
  5. ↑ 5.0 5.1 5.2 Frías JP et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). NEJM 385(6):503–15. doi:10.1056/NEJMoa2107519
  6. ↑ 6.0 6.1 6.2 Coskun T, Sloop KW, Loghin C et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Mol Metab 18:3–14. doi:10.1016/j.molmet.2018.09.009
  7. ↑ Garvey WT, Frias JP, Jastreboff AM et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet 402(10402):613–26. doi:10.1016/S0140-6736(23)01200-X
  8. ↑ 8.0 8.1 Kindel TL et al. (2024). Perioperative GLP-1 receptor agonist safety guidance. Surg Obes Relat Dis 20(12):1183–8.
Summary
Classes
GLP-1 receptor agonist · GIP receptor agonist · Antidiabetic · Anti-obesity · "Twincretin"
Common uses
Pharmacy
Starting dose
2.5 mg SC weekly × 4 wk (non-therapeutic ramp)[1]
Preparations
Pre-filled single-dose pen and vial: 2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg[1][2]
US FDA Max
15 mg/wk SC[1][2]
Pharmacology
Routes
Subcutaneous (abdomen, thigh, upper arm)[1]
Onset
Glycemic effect within days; full weight effect over months[3]
Duration
~7 days (weekly dosing)[1]
Half-life
~5 days (~120 h)[1]
Bioavailability
SC ~80%[citation needed]
Pregnancy
Avoid. Discontinue ≥1 month pre-conception. May reduce oral contraceptive efficacy during titration.[1]
Legal status
Rx-only;[1] not a controlled substance
Purported mechanism
Dual agonist of the GIP receptor and GLP-1 receptor ("twincretin").
Retrieved from "https://pharmacopedia.wiki/index.php?title=Tirzepatide&oldid=4692"